Women’s Life Sciences Network

Spring 2021 – Interview with Samantha Atkinson, Interim Chief Quality & Access Officer at Medicines and Healthcare products Regulatory Agency

February 12, 2020 (Brussels) – Presentation by Isabel de la Mata, Principal Adviser for Health and Crisis Management, European Commission and Dineke Zeegers Paget, Executive Director, EUPHA

October 15, 2019 (Zurich) – Presentation by Emer Cooke, Director, Regulation of Medicines and other Health Technologies, WHO and Petra Dörr, Former Deputy Executive Director, Swissmedic, followed by a discussion with Nakisa Serry, Corporate Vice President, Associate General Counsel, Celgene International and Melinda Friend, Chief Regulatory Counsel, Colgate-Palmolive

June 25, 2019 (Brussels) – Discussion with Olga Tkachenko, Scientific Policy Officer, DG GROW, European Commission and Petra Zoellner, Senior Manager Regulations and Industrial Policy, MedTech Europe

February 20, 2019 (Brussels) – Discussion with Kristine Peers, General Counsel, European Federation of Pharmaceutical Industries (EFPIA) and Rebecca Wood, Partner, Sidley and Former Chief Counsel, Food and Drug Administration (FDA)

November 7, 2018 (Brussels) – Discussion with Amaryllis Verhoeven, Head of the Intellectual Property Unit (DG GROW F5), European Commission

June 14, 2018 (Brussels) – Presentation by Olga Solomon, Head of Unit, Directorate General for Health & Food Safety (DG SANTE), European Commission

February 21, 2018 (Brussels) – Presentation by Dorthe Poulsen, Chief Legal Adviser, EU and International Coordinator, Danish Medicines Agency

October 18, 2017 (Brussels) – Panel discussion with Stephanie Lane, Director Public Policy, MSD Europe Inc.; Sini Eskola, Director Regulatory Affairs, EFPIA; Elizabeth Kuiper, Director European Affairs, EFPIA

February 8, 2017 (Brussels) – Presentation by Maya Matthews, Deputy Head of Unit, Strategy and Coordination, DG Health and Food Safety, European Commission

October 4, 2016 (Zurich) – Presentation by Andreas Balsiger Betts, Head of Legal Affairs, Swiss Agency for Therapeutic Products (Swissmedic) followed by a discussion with Johanna Friedl-Naderer, Senior Vice President, Head of Europe and Canada, Biogen International GmbH; Nicole Neuhaus, Associate General Counsel, Catalent Pharma Solutions GmbH; Ingrid Sollerer, Global Head Legal, Biopharmaceuticals and Deputy General Counsel, Sandoz International GmbH

May 25, 2016 (Brussels) – Discussion with Lenita Lindström-Gommers, Senior Expert, European Commission, DG Health and Food Safety

February 4, 2016 (Brussels) – Discussion with Nathalie Moll, Secretary General, EuropaBio

September 16, 2015 (Brussels) – Discussion with Nina Cromnier, Chair Management Board, European Chemicals Agency (ECHA); Director General, Swedish Chemicals Agency

June 24, 2015 (Brussels) – Discussion with Emma Trogen, Director, Legal Affairs, Cosmetics Europe and Giulia Ciarlo, Policy Advisor, Health Technology and Cosmetics Unit, DG GROWTH, European Commission

April 14, 2015 (Paris) – Panel Discussion with Lidia Retkowska-Mika, Co-Chair, DIA EuroMeeting 2015 & Director of Legal Department, Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL); Paula Salmikangas, Chair of Committee for Advanced Therapies (CAT), European Medicines Agency (EMA) & Senior Researcher, Finnish Medicines Agency (FIMEA); Isabelle Clamou, Director, Global Regulatory and R&D Policy – Europe, Amgen

February 5, 2015 (Brussels) – Discussion with Sabine Lecrenier, Head of Unit for Health Technology and Cosmetics, European Commission

October 8, 2014 (London) – Discussion with Emer Cooke, Head of International Affairs, European Medicines Agency (EMA)

June 4, 2014 (Brussels) – Discussion with Isabel de la Mata, Principal Adviser for Health at the Directorate General for Health and Consumers (DG SANCO)

April 3, 2014 (Brussels) – Panel Discussion with Dara Corrigan, Director, Europe Office, U.S. Food and Drug Administration (FDA); Anna Richo, Executive Vice President and General Counsel, UCB